Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby Davies; Gabrielle Gold-Von Simson

doi:10.1007/s00246-013-0731-3

Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby Davies, Gabrielle Gold-Von Simson

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1756
Number of pages	1
Journal	Pediatric Cardiology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1007/s00246-013-0731-3
State	Published - Oct 2013
Externally published	Yes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s00246-013-0731-3

Cite this

@article{385517ce99ab4bd39d6cf17799c0c25f,

title = "Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?",

author = "Shelby Davies and {Gold-Von Simson}, Gabrielle",

year = "2013",

month = oct,

doi = "10.1007/s00246-013-0731-3",

language = "English (US)",

volume = "34",

pages = "1756",

journal = "Pediatric Cardiology",

issn = "0172-0643",